Johan Falkenius

A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors

Michael A. Samuels, Johan Falkenius, Voichita Bar‐Ad et al. · International Journal of Radiation Oncology*Biology*Physics · 2023 · 59 citations · Full text

High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma

Johan Falkenius, Joakim Lundeberg, Hemming Johansson et al. · Melanoma Research · 2013 · 30 citations

Pigment Proteins, Pathology, Dermatology +19

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

Hildur Helgadóttir, Lars Ny, Gustav Ullenhag et al. · JNCI Journal of the National Cancer Institute · 2023 · 22 citations · Full text

Surgical treatment of skeletal metastases in 31 melanoma patients.

Rikard Wedin, Johan Falkenius, Rüdiger J Weiss et al. · PubMed · 2012 · 20 citations

Surgical Oncology, Spinal Cord Injury, Medicine +11

A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results.

Baukelien van Triest, Lars Damstrup, Johan Falkenius et al. · Journal of Clinical Oncology · 2018 · 18 citations

Dna-pk Inhibitor M3814, Radiation Medicine, Dna Double-strand Breaks +15